MediciNova, Inc. (MNOV)
NASDAQ: MNOV · Real-Time Price · USD
2.170
+0.010 (0.46%)
Dec 20, 2024, 4:00 PM EST - Market closed
MediciNova Employees
MediciNova had 13 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$791,845
Market Cap
106.43M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
MDxHealth | 300 |
PetMed Express | 287 |
Champions Oncology | 210 |
Tonix Pharmaceuticals Holding | 103 |
X4 Pharmaceuticals | 93 |
Leap Therapeutics | 54 |
Protara Therapeutics | 27 |
Cardiol Therapeutics | 6 |
MNOV News
- 16 days ago - MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND - GlobeNewsWire
- 5 weeks ago - MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver - GlobeNewsWire
- 5 weeks ago - MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis - GlobeNewsWire
- 2 months ago - MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium) - GlobeNewsWire
- 2 months ago - MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) - GlobeNewsWire
- 3 months ago - MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND - GlobeNewsWire
- 3 months ago - MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting - GlobeNewsWire
- 4 months ago - MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition - GlobeNewsWire